全文获取类型
收费全文 | 8469篇 |
免费 | 498篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 401篇 |
妇产科学 | 149篇 |
基础医学 | 1021篇 |
口腔科学 | 191篇 |
临床医学 | 596篇 |
内科学 | 1691篇 |
皮肤病学 | 152篇 |
神经病学 | 516篇 |
特种医学 | 325篇 |
外科学 | 1258篇 |
综合类 | 170篇 |
一般理论 | 3篇 |
预防医学 | 497篇 |
眼科学 | 358篇 |
药学 | 1000篇 |
中国医学 | 70篇 |
肿瘤学 | 545篇 |
出版年
2023年 | 65篇 |
2022年 | 66篇 |
2021年 | 268篇 |
2020年 | 185篇 |
2019年 | 211篇 |
2018年 | 278篇 |
2017年 | 187篇 |
2016年 | 231篇 |
2015年 | 261篇 |
2014年 | 347篇 |
2013年 | 435篇 |
2012年 | 621篇 |
2011年 | 665篇 |
2010年 | 344篇 |
2009年 | 295篇 |
2008年 | 496篇 |
2007年 | 508篇 |
2006年 | 451篇 |
2005年 | 378篇 |
2004年 | 366篇 |
2003年 | 322篇 |
2002年 | 340篇 |
2001年 | 175篇 |
2000年 | 148篇 |
1999年 | 122篇 |
1998年 | 57篇 |
1997年 | 45篇 |
1996年 | 53篇 |
1995年 | 42篇 |
1994年 | 19篇 |
1993年 | 37篇 |
1992年 | 66篇 |
1991年 | 69篇 |
1990年 | 74篇 |
1989年 | 75篇 |
1988年 | 64篇 |
1987年 | 61篇 |
1986年 | 49篇 |
1985年 | 39篇 |
1984年 | 60篇 |
1983年 | 39篇 |
1982年 | 33篇 |
1981年 | 30篇 |
1980年 | 30篇 |
1979年 | 46篇 |
1978年 | 18篇 |
1977年 | 23篇 |
1974年 | 20篇 |
1973年 | 24篇 |
1970年 | 23篇 |
排序方式: 共有8997条查询结果,搜索用时 22 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
Raya Saab MD Anas Obeid MD Fatiha Gachi MD Houda Boudiaf MD Lilit Sargsyan MD Khulood Al-Saad MD Tamar Javakhadze MD Azim Mehrvar MD Sawsan Sati Abbas MD Yasir Saadoon Abed Al-Agele MD Salma Al-Haddad MD Mouroge Hashim Al Ani MD Suleiman Al-Sweedan MD Amani Al Kofide MD Wasil Jastaniah MD Nisreen Khalifa MD Elie Bechara MD Malek Baassiri MD Peter Noun MD Jamila El-Houdzi MD Mohammed Khattab MD Krishna Sagar Sharma MD Yasser Wali MD Naureen Mushtaq MD Aliya Batool MD Mahwish Faizan MD Muhammad Rafie Raza MD Mohammad Najajreh MD Mohammed Awad Mohammed Abdallah MD Ghada Sousan MD Khaled M. Ghanem MD Ulker Kocak MD Tezer Kutluk MD Hacı Ahmet Demir MD Hamoud Hodeish MD Samar Muwakkit MD Asim Belgaumi MD Abdul-Hakim Al-Rawas MD Sima Jeha MD 《Cancer》2020,126(18):4235-4245
3.
4.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
5.
Rimesh Pal Naresh Sachdeva Soham Mukherjee Vikas Suri Deepy Zohmangaihi Sant Ram Goverdhan Dutt Puri Ashish Bhalla Shiv Lal Soni Navin Pandey Anil Bhansali Sanjay Kumar Bhadada 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):193-196
Background and aimsPatients with diabetes mellitus (DM) often demonstrate impaired antibody response to influenza/hepatitis B vaccines. Hence, we compared anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with and without type 2 diabetes mellitus (T2DM).MethodsRecords of non-severe COVID-19 patients admitted at our institution between April 10, 2020 and May 20, 2020 were retrieved. Qualitative detection of total (IgG + IgM) anti-SARS-CoV-2 antibody was performed using electrochemiluminescence immunoassay in plasma samples collected at least 14 days post-polymerase chain reaction (PCR) confirmation of diagnosis.ResultsThirty-one non-severe COVID-19 patients were included. Nine patients (29%) had T2DM with mean HbA1c at admission of 8.3 ± 1.0%. Anti-SARS-CoV-2 antibody was estimated at a median of 16 (14–17) days post-PCR confirmation of COVID-19 diagnosis. Only three patients (10%) were seronegative, and all had T2DM. Patients with T2DM were more likely to have non-detectable anti-SARS-CoV-2 antibodies than those without DM (p = 0.019).ConclusionsCOVID-19 patients with T2DM may not undergo seroconversion even after two weeks of diagnosis. Impaired seroconversion could theoretically increase the risk of reinfections in patients with DM. However, the finding requires validation in large-scale studies involving serial estimations of anti-SARS-CoV-2 antibodies in patients with and without DM. 相似文献
6.
7.
8.
Krishna S. Iyer 《Platelets》2020,31(4):474-482
Abstract Platelets are small, anucleated effector cells that play an important role in linking the hemostatic and inflammatory processes in the body. Platelet function is known to be altered under various inflammatory conditions including aging. A gain in platelet function during aging can increase the risk of thrombotic events, such as stroke and acute myocardial infarction. Anti-platelet therapy is designed to reduce risk of serious cerebrovascular and cardiovascular events, but the adverse consequences of therapy, such as risk for bleeding increases with aging as well. Age-associated comorbidities such as obesity, diabetes, and hyperlipidemia also contribute to increased platelet activity and thus can enhance the risk of thrombosis. Therefore, identification of unique mechanisms of platelet dysfunction in aging and in age-associated comorbidities is warranted to design novel antiplatelet drugs. This review outlines some of the current areas of research on aging-related mechanisms of platelet hyperactivity and addresses the clinical urgency for designing anti-platelet therapies toward novel molecular targets in the aging population. 相似文献
9.
10.
Roman Viter Kwanele Kunene Povilas Genys Daniels Jevdokimovs Donats Erts Andris Sutka Krishna Bisetty Arturs Viksna Almira Ramanaviciene Arunas Ramanavicius 《Macromolecular chemistry and physics.》2020,221(2)
Molecularly imprinted polymers are important tools for the design of sensors and other molecular recognition based analytical systems. In this paper the development of a photoelectrochemical sensor for selective bisphenol determination is reported. The sensor is based on a glass/ZnO/MIP‐Ppy structure consisting of glass modified by a ZnO layer (glass/ZnO), which is functionalized by molecularly imprinted conducting polymer polypyrrole (MIP‐Ppy). The sensitivity of the sensor to bisphenol is in the range of 0.7–12.5 µm . Selectivity tests to other bisphenolic compounds are performed. Some aspects of a photoinduced response mechanism in glass/ZnO/MIP‐Ppy nanostructures are predicted and discussed. 相似文献